BRPI1009781A2 - compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos - Google Patents
compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmosInfo
- Publication number
- BRPI1009781A2 BRPI1009781A2 BRPI1009781A BRPI1009781A BRPI1009781A2 BR PI1009781 A2 BRPI1009781 A2 BR PI1009781A2 BR PI1009781 A BRPI1009781 A BR PI1009781A BR PI1009781 A BRPI1009781 A BR PI1009781A BR PI1009781 A2 BRPI1009781 A2 BR PI1009781A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- treatment
- pharmaceutical compositions
- metabolic disorders
- metabolic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0904287.0A GB0904287D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
PCT/GB2010/050442 WO2010103335A1 (en) | 2009-03-12 | 2010-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1009781A2 true BRPI1009781A2 (pt) | 2016-03-08 |
Family
ID=40600949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1009781A BRPI1009781A2 (pt) | 2009-03-12 | 2010-03-12 | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120040953A1 (pt) |
EP (1) | EP2406256A1 (pt) |
JP (1) | JP2012520284A (pt) |
KR (1) | KR20110130476A (pt) |
CN (1) | CN102395584A (pt) |
AU (1) | AU2010222673A1 (pt) |
BR (1) | BRPI1009781A2 (pt) |
CA (1) | CA2754794A1 (pt) |
CL (1) | CL2011002221A1 (pt) |
EA (1) | EA201190209A1 (pt) |
GB (1) | GB0904287D0 (pt) |
IL (1) | IL215051A0 (pt) |
MA (1) | MA33242B1 (pt) |
MX (1) | MX2011009491A (pt) |
PE (1) | PE20120356A1 (pt) |
SG (1) | SG174362A1 (pt) |
WO (1) | WO2010103335A1 (pt) |
ZA (1) | ZA201107446B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
JP2012530758A (ja) | 2009-06-24 | 2012-12-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物、医薬組成物及びそれに関する方法 |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB2488360A (en) * | 2011-02-25 | 2012-08-29 | Prosidion Ltd | Heterocyclic GPCR agonists |
GB201114389D0 (en) * | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
AR083904A1 (es) * | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
KR101881932B1 (ko) | 2011-12-07 | 2018-07-27 | 삼성전자주식회사 | 자기 소자 및 그 제조 방법 |
JP2015522080A (ja) | 2012-07-11 | 2015-08-03 | エルセリクス セラピューティクス インコーポレイテッド | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 |
WO2018165520A1 (en) * | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
WO2021009209A1 (en) * | 2019-07-15 | 2021-01-21 | Oncoarendi Therapeutics S.A. | Substituted amino triazoles useful as chitinase inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
JP2002523090A (ja) | 1998-09-01 | 2002-07-30 | ビーエーエスエフ アクチェンゲゼルシャフト | 異種gタンパク質共役受容体の増強された機能的発現 |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
NZ547965A (en) * | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
CA2591922A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Limited | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
GB0513257D0 (en) * | 2005-06-30 | 2005-08-03 | Prosidion Ltd | Compounds |
BRPI0613505A2 (pt) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
CN101379028A (zh) | 2006-02-09 | 2009-03-04 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
MX2008012814A (es) | 2006-04-06 | 2008-10-17 | Prosidion Ltd | Agonistas del receptor acoplado a la proteina g heterociclicos. |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
ES2374952T3 (es) | 2006-12-06 | 2012-02-23 | Glaxosmithkline Llc | Compuestos bicíclicos y uso como antidiabéticos. |
EP2114925B8 (en) | 2006-12-22 | 2013-04-10 | Industrial Research Limited | Azetidine analogues of nucleosidase and phosphorylase inhibitors |
PT2114933E (pt) | 2007-01-04 | 2011-12-20 | Prosidion Ltd | Agonistas do gpcr de piperidina |
CA2674360A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
CN103550218A (zh) | 2007-07-17 | 2014-02-05 | 百时美施贵宝公司 | 用于调节gpr119 g蛋白偶联受体的方法及所选化合物 |
EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
JP4455675B2 (ja) | 2007-10-18 | 2010-04-21 | 日鉱金属株式会社 | 金属被覆ポリイミド複合体及び同複合体の製造方法並びに電子回路基板の製造方法 |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
KR20110036609A (ko) | 2008-07-10 | 2011-04-07 | 프로시디온 리미티드 | 피페리디닐 gpcr 작용제 |
GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
ATE557024T1 (de) | 2008-07-10 | 2012-05-15 | Prosidion Ltd | Piperidinverbindungen als gpcr-agonisten |
-
2009
- 2009-03-12 GB GBGB0904287.0A patent/GB0904287D0/en not_active Ceased
-
2010
- 2010-03-12 MX MX2011009491A patent/MX2011009491A/es unknown
- 2010-03-12 EA EA201190209A patent/EA201190209A1/ru unknown
- 2010-03-12 US US13/255,536 patent/US20120040953A1/en not_active Abandoned
- 2010-03-12 PE PE2011001633A patent/PE20120356A1/es not_active Application Discontinuation
- 2010-03-12 CA CA2754794A patent/CA2754794A1/en not_active Abandoned
- 2010-03-12 CN CN2010800164285A patent/CN102395584A/zh active Pending
- 2010-03-12 EP EP10709926A patent/EP2406256A1/en not_active Withdrawn
- 2010-03-12 KR KR1020117024020A patent/KR20110130476A/ko not_active Application Discontinuation
- 2010-03-12 JP JP2011553534A patent/JP2012520284A/ja active Pending
- 2010-03-12 WO PCT/GB2010/050442 patent/WO2010103335A1/en active Application Filing
- 2010-03-12 MA MA34246A patent/MA33242B1/fr unknown
- 2010-03-12 AU AU2010222673A patent/AU2010222673A1/en not_active Abandoned
- 2010-03-12 SG SG2011065794A patent/SG174362A1/en unknown
- 2010-03-12 BR BRPI1009781A patent/BRPI1009781A2/pt not_active Application Discontinuation
-
2011
- 2011-09-08 CL CL2011002221A patent/CL2011002221A1/es unknown
- 2011-09-08 IL IL215051A patent/IL215051A0/en unknown
- 2011-10-11 ZA ZA2011/07446A patent/ZA201107446B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110130476A (ko) | 2011-12-05 |
IL215051A0 (en) | 2011-11-30 |
GB0904287D0 (en) | 2009-04-22 |
US20120040953A1 (en) | 2012-02-16 |
JP2012520284A (ja) | 2012-09-06 |
EP2406256A1 (en) | 2012-01-18 |
CA2754794A1 (en) | 2010-09-16 |
EA201190209A1 (ru) | 2012-04-30 |
ZA201107446B (en) | 2012-06-27 |
MA33242B1 (fr) | 2012-05-02 |
PE20120356A1 (es) | 2012-04-16 |
CL2011002221A1 (es) | 2012-07-06 |
MX2011009491A (es) | 2011-10-11 |
AU2010222673A1 (en) | 2011-11-03 |
SG174362A1 (en) | 2011-11-28 |
CN102395584A (zh) | 2012-03-28 |
WO2010103335A1 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1009781A2 (pt) | compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos | |
BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BRPI1013640A2 (pt) | composicao farmaceutica, metodos para o tratamento e usos dos mesmos | |
BR112013011949A2 (pt) | "indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis" | |
BRPI0811635A2 (pt) | Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos | |
BRPI0820665A2 (pt) | compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos | |
BRPI0817200A2 (pt) | composições oftálmicas sólida e uso de compostos para fabricação de medicamento | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BR112014009932A2 (pt) | derivados de hidroxamato para inibidores da hdac e composição farmacêutica contendo os mesmos | |
BRPI1005153A2 (pt) | composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2013001604A1 (es) | Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis. | |
BRPI0807907A2 (pt) | co-cristais e composições farmacêuticas compreendendo os mesmos. | |
BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
CL2013000801A1 (es) | Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |